“Treatment Outcome in Patients With HCV Genotype-3a Infection, Treated With 24-Weeks Dual Therapy (Sofosbuvir and Ribavirin)”. Medical Forum Monthly, vol. 28, no. 11, May 2024, https://medicalforummonthly.com/index.php/mfm/article/view/4275.